Know Cancer

forgot password

Physician Alerts to Prevent DVT and Pulmonary Embolism in Hospitalized Patients

18 Years
Not Enrolling
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery

Thank you

Trial Information

Physician Alerts to Prevent DVT and Pulmonary Embolism in Hospitalized Patients

Background Information and Rationale for the Study:

Venous thromboembolism (VTE) is often avoidable in hospitalized patients because proven
prevention strategies have been established for patients at risk. North American and
European prophylaxis guidelines have been widely disseminated. However, despite intensive
educational efforts, VTE prevention remains underutilized.

At Brigham and Women's Hospital, we undertook a comprehensive program aimed at increasing
the frequency of VTE prophylaxis in high risk patients. This novel strategy required: 1)
devising a risk score that reliably and quickly identified patients at high risk of VTE, and
2) conducting a randomized controlled trial in which high risk patients without prophylaxis
were randomized into an intervention or control group. The intervention group's physicians
received a single alert explaining that the patient was at high risk, was not receiving
prophylaxis, and urged that prophylaxis be selected from a template of available
pharmacological and mechanical options. In contrast, the control group's physicians
received no alert.

Each of 8 common risk factors was weighted according to a point scale. At least 4 score
points were required to be deemed at "high risk" for VTE.

3 of the 8 risk factors were considered major and were assigned a score of 3 points each:

1. Cancer

2. Prior VTE

3. Hypercoagulability

One of the 8 risk factors, surgery, was considered intermediate and was assigned a score of

4 of the 8 risk factors were considered minor and were assigned a score of 1 point each:

1. Advanced age (> 70 years of age)

2. Obesity (Body Mass Index > 29)

3. Bed rest

4. Hormone replacement therapy or oral contraceptives

There were 2,506 patients in the randomized controlled trial of a computer alert: 1255 in
the intervention group and 1251 in the control group. The incidence of symptomatic VTE at
90 days was high: 8.2% in the control group. This high incidence validates the 8 risk
factor and point score methodology.

The intervention group had an overall 41% reduction in VTE, without any increase in major
bleeding. There was a 60% reduction in the incidence of symptomatic pulmonary embolism.

Identification of Patients at Risk for Venous Thromboembolism (VTE):

A VTE risk profile will be computed for each hospitalized patient using 8 common risk
factors. Each risk factor is weighted according to a point score. To be included in this
trial, the point score must equal or exceed 4 points.

Minor (Low) Risk Factors (1 POINT each):

- Advanced Age (>70 years of age)

- Obesity (BMI >29, or the presence of the word "obesity" in admission exam notes)

- Bed rest / Immobility (not related to surgery)

- Female Hormone Replacement Therapy or Oral Contraceptives

Intermediate Risk Factor (2 POINTS each):

· Major Surgery (> 60 minutes)

Major (High) Risk Factors (3 POINTS each):

- Cancer (active)

- Prior VTE

- Hypercoagulability

Increased VTE risk is defined as a cumulative VTE risk score 4, so that patients with at
least 1 major risk factor (cancer, prior VTE, or hypercoagulability) plus at least 1
additional intermediate risk factor (major surgery or bed rest) or minor risk factor
(advanced age, obesity, or hormone replacement therapy/oral contraceptives) become eligible.
In the absence of a major risk factor, patients with 1 intermediate risk factor plus at
least 2 minor risk factors become eligible.

Screening for Venous Thromboembolism Prophylaxis:

If the cumulative VTE risk score is ³4, orders are reviewed to detect ongoing mechanical or
pharmacological prophylactic measures. Mechanical prophylactic measures include graduated
compression stockings and intermittent pneumatic compression devices. Pharmacological
prophylactic measures include unfractionated heparin, enoxaparin, dalteparin, fondaparinux,
tinzaparin, and warfarin.


Randomization Envelopes containing the statement "ALERT" (Intervention) or "NO ALERT"
(Control) will be provided by Harvard Clinical Research Institute (HCRI), to randomize
patients who meet all inclusion criteria.

The intervention is informing the responsible physician that: 1) his or her patient is at
high risk for VTE, 2) is not receiving prophylaxis, and 3) VTE prophylaxis is recommended.
For control patients, VTE prevention guidelines are available, but no specific prompt is
provided to use them.

Follow Up:

Ninety-day follow-up is performed in all study patients by medical record review and through
contact with the subject's Primary Care Physician.

Data Collection and Study Endpoints:

The primary endpoint is clinically diagnosed DVT or PE at 90 days. Safety endpoints include
total mortality and hemorrhagic events at 30 and 90 days, respectively. We define major
bleeding as intracranial, intraocular, retroperitoneal, pericardial, or bleeding that
requires surgical intervention or that resulted in a hemoglobin loss greater than 3 g/l.

DVT is diagnosed if there is loss of vein compressibility by ultrasound or a filling defect
by CT scan or by conventional contrast venography. PE is diagnosed by a positive contrast
chest CT scan, a high-probability ventilation perfusion scan, or conventional pulmonary

Inclusion Criteria:

- Patients > 18 years of age

- Cumulative VTE risk score > 4

- Absence of pharmacologic or mechanical prophylaxis orders

- Patients from medical or surgical Services

Exclusion Criteria:

- VTE risk score <4

- Current active pharmacologic or mechanical prophylaxis order

- Patients from the Department of Neurology, Newborn Service, Rehab Units, and Neonatal
Intensive Care Unit (NICU).

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Clinically diagnosed DVT and/or PE

Outcome Time Frame:

90 days

Safety Issue:


Principal Investigator

Samuel Z. Goldhaber, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Brigham and Women's Hospital


United States: Institutional Review Board

Study ID:




Start Date:

March 2006

Completion Date:

August 2008

Related Keywords:

  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Cancer
  • Surgery
  • Alert
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Venous Thromboembolism
  • Prophylaxis
  • Anticoagulation
  • Embolism
  • Pulmonary Embolism
  • Thrombosis
  • Venous Thrombosis



LDS Hospital Salt Lake City, Utah  84143
North Shore University Hospital Manhasset, New York  11030
University of Missouri Columbia, Missouri  65212
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma  73104
William W. Backus Hospital Norwich, Connecticut  06360
Spartanburg Regional Medical Center Spartanburg, South Carolina  29303
Washington Hospital Center Washington, District of Columbia  20010
Presbyterian Hospital of Dallas Dallas, Texas  75231
St. Joseph Mercy Hospital Pontiac, Michigan  48341-2985
University of Colorado Health Sciences Center Denver, Colorado  80262
Lahey Clinic Burlington, Massachusetts  01805
Florida Hospital Orlando, Florida  32803
Norwalk Hospital Norwalk, Connecticut  06856
Washington County Hospital Hagerstown, Maryland  21740
University of California - Irvine Orange, California  92868
Franklin Square Hospital Baltimore, Maryland  21237
University of California - Davis Davis, California  95616
AZ Pulmonary Specialists, Ltd Scottsdale, Arizona  85258
Long Beach VA Hospital Long Beach, California  90822
Emory-Crawford Long Hospital Atlanta, Georgia  30308
North Shore Medical Center Salem, Massachusetts  01970
Henry Ford Hospital K15 Detroit, Michigan  48202
Thomas Jefferson Hospital Philadelphia, Pennsylvania  19107
Washington Hospital Washington, Pennsylvania  15301
University of Utah Medical Center Salt Lake City, Utah  84132
United Hospital System Kenosha, Wisconsin  53143